Introduction: Children with steroid resistant nephrotic syndrome usually require treatment with second-line agents and calcineurin inhibitors such
Introduction
Nephrotic Syndrome (NS) is a glomerular disease characterized by severe proteinuria, hypoalbuminemia, anasarca and hypercholesterolemia [1] . The idiopathic form accounts for about 90% of cases and responds to first-line therapy with corticosteroids in about 80% of affected children [1] . The remaining steroid resistant group often constitutes a management challenge with higher incidences of infections, complications of steroid toxicity as well as progression to Chronic Kidney Disease (CKD) and End Stage
Kidney Disease (ESKD) [2] .
Efforts to improve the outcome of children with idiopathic steroid resistant nephrotic syndrome (iSRNS) have resulted in the emergence of various steroid sparing agents with considerations for sustained remission and reduced side effects. These include alkylating agents such as cyclophosphamide (CYC), calcineurin inhibitors such as cyclosporine (CsA) and tacrolimus, mycophenolate mofetil (MMF), a T and B cell proliferation inhibitor and rituximab, a monoclonal antibody generally reserved for multi-therapy resistant cases. These have been used singly or in combination with wide variations in practice among pediatric nephrologists worldwide and consequently, varying outcomes [3] [4] [5] [6] . In order to standardize care, the Kidney Disease: Improving Global Outcomes (KDIGO) group [7] in 2012, made several recommendations on the treatment of childhood idiopathic SRNS. These include the use of calcineurin inhibitors as the first line drugs for the management of steroid resistant nephrotic syndrome which we have since adopted at our centre. The objective of this study therefore was to determine the short-term outcome of the treatment of childhood iSRNS with cyclosporine, and compare this with outcome prior to adoption of the KDIGO guidelines.
Methods

Study centre
The study was conducted at the Paediatric Nephrology Unit of the Lagos University Teaching Hospital in Southwest Nigeria. Data of all children diagnosed with sephrotic syndrome (serum albumin<25g/L, spot urine protein: creatinine ratio >200mg/mmol, generalized oedema and serum cholesterol > 5.2mmol/l) [1, 7] between January 2009 and December 2014 was analyzed. Children who were followed up for less than 3 months or those with incomplete data were excluded from the study. and ANCA were only performed, due to cost constraints, as indicated. Glomerular filtration rate (eGFR) was estimated in using the modified Schwartz formula [8] . Chronic kidney disease (CKD)
was defined according to the Kidney Disease Outcomes Qualitative
Initiative (KDOQI) guidelines [9] . A diagnosis of idiopathic nephrotic syndrome was made in the absence of a secondary cause for nephrotic syndrome.
Treatment regimen
All patients with idiopathic NS received oral prednisolone at 60mg/m2 daily for 4-6 weeks. CsA, serum levels were checked two to four weeks after commencing the medication and then subsequently 2-3 monthly or as indicated as cost permitted. Dosages were adjusted to maintain trough levels at 70-120ng/ml. CsA resistance was diagnosed following failure of remission after 6 months of treatment. Primary outcome of treatment with CsA was remission at 6months while secondary outcome was progression to end-stage kidney disease.
Statistical analysis
Data were analyzed using the Statistical Package for Social Sciences software version 20. Continuous data were represented as means and standard deviations or median and range as appropriate while categorical data were presented as percentages. Chi-square test was used to determine the association between categorical data while student t test was used for comparison of means. Correlation between some variables and likelihood of remission was determined using Pearson's correlation co-efficient. Statistical significance was set <0.05.
Results
Of the 129 children managed for NS during the study period, 103
had the idiopathic form (iNS) of whom 25(24.3%) were steroid resistant. Children with iSRNS were aged between 0.6-15.2years
(median 8.8) with the majority (64%) being >5years. A summary of their baseline characteristics is shown in Table 1 . Median age was significantly higher in children with idiopathic SRNS compared with the steroid sensitive form (9.1 vs 5years respectively, p=0.008) Two children were referred to other centers on request, one died from complications of acute kidney injury before treatment for SRNS could be commenced while five defaulted from follow-up.
Treatment of iSRNS
A summary of the treatment response of the remaining 17 children is shown in Table 2 and Table 3 Two children developed 1+ proteinuria at serum CsA levels <30ng/ml which resolved once the doses were increased, A summary of response to treatment is shown in Figure 1 .
With regards to renal function, median serum creatinine at presentation was 56.5µmol/l with 6 children having serum creatinine greater than 88µmol/l. The estimated Glomerular filteration rate (eGFR) (ml/min/1. Several studies also report similar good outcomes with use of CsA.
In Tunisia [11] , overall remission rates among 30 children with iSRNS following a CsA-prednisone combination was 80%, howbeit partial in 30% of children. Progression to ESRD was however higher in their study occurring in 9 (30%) patients for reasons which are not very clear. Similarly, in Japan [12] , remission rates of 82-85%
were reported among 30 children with iSRNS treated for 121 months. However, in this latter study [12] , children with FSGS additionally received pulse methylprednisolone which may have contributed to the higher remission rates observed.
In Iran [13] , complete and partial remission rates of 32.4% and 5.4% were reported among 37 children treated with CsA and prednisolone combination for 6 months while remission rates of 53% and 65% were reported from Saudi Arabia [14] and Brazil [15] respectively. It is important to highlight the fact that differences in treatment duration before diagnosis of CsA resistance in the aforementioned studies exist and may account for variability in reported CsA response rates. For instance, while response to CsA was determined after 4 months in Tunisia and Japan [11, 12] , in Iran (13) and Brazil [15] , diagnosis was made after 6months of failure of at least partial remission as recommended by the KDIGO and as was the case in the current study. Non-uniformity of access to drugs due to cost-constraints may be another contributing factor as experienced in the group from Saudi Arabia [14] who attributed their lower remission rates to inadequate therapy due to financial and social difficulties. Similarly, one patient in our cohort developed treatment failure from non-compliance excluding which our remission rate would have been 80%. The high remission rate we have nonetheless reported may not be unrelated to the fact that
CsA is relatively new in our environment, hence giving little time for emergence of resistance, but this is purely speculative.
Outcome with CsA has been shown to be improved when combined with other immune-suppressants such as MMF [13, 16] . In Iran [13] , among 23 children who were CsA resistant, complete remission was observed in 11 cases (47.82%) and partial remission in 2 cases (8.7%) after combined MMF and CsA therapy thus increasing the overall remission rate. Such improved outcome has also been reported with other immunosuppressant combinations [5] . We currently have limited experience with MMF as majority of our patients achieved remission with cyclosporine. Only two of our patients eventually received MMF, one of whom has been lost to follow-up while the other was transferred to another centre for follow-up. Tacrolimus, another calcineurin inhibitor is not commonly used at our centre because of it's high cost. Rituximab, a monoclonal antibody which is generally reserved for refractory cases of NS [6] was shown in a recent meta-analysis to have a higher rate of complete remission and significantly improved relapse-free survival compared with other immunotherapies. Further studies are however required to determine its long term effects. Short term side effects of CsA in our cohort were minimal with only one patient switching to MMF on account of acne. Similarly, only one of our patients developed gum hypertrophy which was reported in 6 patients in Saudi Arabia [14] . The major constraint to the shortterm use of CsA in our environment therefore is the cost, both of the drug and of serum level determination which precluded the monitoring of serum levels as desired. Long term use remains controversial because of it's association with nephrotoxicity [17, 18] , a side effect of major concern, although there are suggestions that long-term use in moderate doses with closely monitored levels can reduce it's incidence [18] . CsA has also been associated with a high rate of relapse after discontinuation of the drug [17] and optimal duration of treatment remains undetermined.
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Our combined remission rates using cyclophosphamide or enalapril with alternate day prednisolone of 50% is similar to that from another Nigerian study [19] that reported a cumulative remission rate of 57.12% with use of pulse intravenous cyclophosphamide and intravenous dexamethasone ± lisinopril or spironolactone. In contrast to this, amongst three children treated with cyclophosphamide in the USA [5] , only one (33.3%) achieved partial remission while 2 were CYC resistant while in Iran [20] , 10 out of 41 (24.4%) patients with iSRNS responded to cyclophosphamide.
These studies demonstrate the superiority of CsA over CYC in the management of iSRNS both in efficacy and side effect profile as has been highlighted by the KDIGO [7] . In our cohort, CsA also resulted in improved renal survival as only 1 patient, who was non-compliant with treatment progressed to ESKD.
Histological patterns from our study were FSGS, MCNS and MPGN in order of predominance agreeing with the general pattern in other studies [3, 5, 11, 14, 19] . The KDIGO [7] recommends a kidney biopsy for all children with SRNS before instituting therapy, even though opinions on the relationship between histological type and response to treatment differ [11, 13] . A kidney biopsy nevertheless remains important as it aids in the diagnosis of secondary causes, is important in disease prognostication [7] and helps in identifying changes in disease epidemiology. It however does not influence the choice of medication in children with idiopathic steroid resistant nephrotic syndrome. Identifying factors that may predict outcome may be useful in prognostication. In this study, only serum cholesterol at presentation was significantly associated with remission. Lower serum albumin levels at presentation has also been negatively associated with remission [11] and even though this was so in our study, the association was not statistically significant.
A limitation of this study was our inability to correlate serum levels of CsA with remission though none of our patients experienced relapses or increased proteinuria with CsA serum levels above 50ng/ml. This study also looked only at short -term outcome hence we are unable to determine the rate of sustained remission though patients are still under follow-up.  There is a need for long-term studies to determine optimal duration of treatment with cyclosporine as well as controlled studies comparing outcome with other newer immunosuppressants in our environment.
Conclusion
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